Want to see DTIL full AI Analyst Report?
Top Page
Precision BioSciences
(NASDAQ:DTIL)
Select Model
Select Model
Rating:51Neutral
Price Target:
$9.00
▲(6.01% Upside)
Action:Reiterated
Date:08/24/26
The score is held back primarily by weak financial performance (ongoing losses, declining equity, and substantial cash burn). Offsetting this somewhat are constructive technical momentum (price above key moving averages with positive MACD) and positive corporate catalysts tied to clinical trial progress and improved debt maturity profile, while valuation is constrained by negative earnings and no dividend.
Positive Factors
DMD pipeline reaches clinical testing
Beginning a clinical trial for PBGENE-DMD advances a wholly owned asset toward human validation. Its potential reach across a large DMD mutation hotspot and design to restore near full-length dystrophin could support meaningful long-term development value.
Negative Factors
Severe and persistent cash burn
The company is consuming substantial cash to fund operations without commercial product revenue. If this burn persists through clinical development, Precision may need external financing, potentially limiting strategic flexibility and increasing dilution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
DMD pipeline reaches clinical testing
Beginning a clinical trial for PBGENE-DMD advances a wholly owned asset toward human validation. Its potential reach across a large DMD mutation hotspot and design to restore near full-length dystrophin could support meaningful long-term development value.
Read all positive factors
Precision BioSciences (DTIL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$235.99M
Dividend YieldN/A
Average Volume (3M)529.58K
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue Growth3472.96%
EPS Growth67.74%
CountryUS
Employees67
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.79
Shares Outstanding27,601,555
10 Day Avg. Volume380,086
30 Day Avg. Volume529,584
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.58
Price to Sales (P/S)1.56
P/FCF Ratio-0.81
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.00Price Target Upside288.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.47
Revenue Forecast (FY)$13.19M
Precision BioSciences Business Overview & Revenue Model
Company Description
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary gen...
How the Company Makes Money
Precision BioSciences generates revenue primarily through collaboration and licensing arrangements tied to its ARCUS genome editing platform rather than from product sales (as it has been a clinical-stage company). These arrangements typically inc...
Precision BioSciences Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 45.05M | 34.26M | 68.70M | 48.73M | 25.10M | 115.53M |
| Gross Profit | 45.05M | 34.26M | 68.70M | 48.73M | 25.10M | 115.53M |
| EBITDA | -50.05M | -42.43M | 13.53M | -32.04M | -62.79M | -20.27M |
| Net Income | -52.73M | -45.72M | 7.17M | -61.32M | -111.64M | -30.60M |
Balance Sheet | ||||||
| Total Assets | 125.92M | 154.42M | 136.39M | 159.78M | 238.17M | 211.50M |
| Cash, Cash Equivalents and Short-Term Investments | 87.55M | 115.58M | 86.31M | 116.68M | 189.58M | 143.66M |
| Total Debt | 28.10M | 28.81M | 30.05M | 31.27M | 24.96M | 9.11M |
| Total Liabilities | 80.63M | 62.17M | 80.00M | 140.92M | 177.74M | 120.33M |
| Stockholders Equity | 45.29M | 92.25M | 56.39M | 18.86M | 60.43M | 91.17M |
Cash Flow | ||||||
| Free Cash Flow | -51.95M | -65.93M | -58.70M | -86.39M | -49.07M | -16.66M |
| Operating Cash Flow | -51.90M | -65.84M | -58.45M | -84.11M | -45.75M | -10.85M |
| Investing Cash Flow | -421.00K | -634.00K | -215.00K | 5.83M | -3.32M | -5.80M |
| Financing Cash Flow | 79.92M | 95.16M | 50.45M | 5.39M | 94.98M | 70.52M |
Precision BioSciences Risk Analysis
Precision BioSciences disclosed 75 risk factors in its most recent earnings report. Precision BioSciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Precision BioSciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $235.99M | -3.04 | -91.60% | ― | 3472.96% | 67.74% | |
51 Neutral | $734.32M | -7.38 | -38.46% | ― | -87.03% | -179.91% | |
51 Neutral | $84.25M | -0.78 | -74.90% | ― | ― | 44.73% | |
48 Neutral | $93.42M | -1.11 | -70.14% | ― | ― | 16.04% | |
45 Neutral | $63.00M | -1.04 | -35.20% | ― | ― | 31.98% |
* Healthcare Sector Average
DTIL
Precision BioSciences
8.49
3.47
69.12%
CTMX
CytomX Therapeutics
3.32
1.27
61.95%
ACET
Adicet Bio
8.95
-3.19
-26.26%
IMA
ImageneBio
5.43
-8.03
-59.66%
ACRV
Acrivon Therapeutics, Inc.
2.08
0.75
56.39%
Precision BioSciences Corporate Events
Business Operations and StrategyProduct-Related Announcements
Precision BioSciences Begins First DMD Gene-Editing Trial
Positive
Aug 24, 2026
On August 24, 2026, Precision BioSciences announced that it had dosed the first patient in its Phase 1/2 FUNCTION-DMD clinical trial of PBGENE-DMD at Arkansas Children’s Hospital, marking the first clinical gene-editing program for Duchenne ...
Business Operations and StrategyExecutive/Board Changes
Precision BioSciences Announces Key Executive Leadership Changes
Positive
Jul 27, 2026
On July 23, 2026, Precision BioSciences’ board approved a series of senior leadership changes effective August 1, 2026, including promoting Chief Financial Officer Alex Kelly to the newly created role of Chief Operating Officer to oversee ke...
Business Operations and StrategyProduct-Related Announcements
Precision BioSciences Advances Gene-Editing Programs in Hepatitis B
Positive
Jul 1, 2026
Precision BioSciences, Inc. is a biotechnology company focused on developing gene-editing therapies targeting serious chronic and genetic diseases. Its pipeline includes programs for chronic hepatitis B and Duchenne muscular dystrophy, positioning...
Business Operations and StrategyPrivate Placements and Financing
Precision BioSciences Extends Term Loan Maturity to 2029
Positive
Jun 16, 2026
On June 10, 2026, Precision BioSciences, Inc. amended its existing loan and security agreement with Banc of California, entering into a first amendment that modifies the terms of its term loan facility. Under the revised agreement, the maturity da...
Business Operations and StrategyProduct-Related Announcements
Precision BioSciences Reports Promising New Hepatitis B Trial Data
Positive
May 27, 2026
On May 27, 2026, Precision BioSciences reported new and late-breaking clinical and biopsy data from its ongoing Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B, presented at the European Association for the Study of the Liver Congre...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Precision BioSciences Shareholders Approve Incentive Plan and Directors
Positive
May 26, 2026
On May 21, 2026, Precision BioSciences held its annual meeting of stockholders, where shareholders approved an amended and restated 2019 Incentive Award Plan that increases the pool of shares available for equity-based compensation by 3,800,000 sh...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.